Unibest

Pharmaceutical intermediates

Ceritinib Intermediates

5 pharmaceutical intermediates for Ceritinib. Indication: Non-small cell lung cancer.

提交项目All intermediates

About Ceritinib

Originator
Novartis Pharmaceuticals Corp
Indication
Non-small cell lung cancer
Approved Date
04/29/2014
DS/DP
04/25/2026

Available intermediates

5 intermediates currently listed for Ceritinib. Request specifications, documentation or a quotation for any item below.

Ceritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,5-Dichloro-N-(2-(isopropylsulfonyl)phenyl)pyrimidin -4-amine761440-16-8//
2-Isopropylthioaniline hydrochloride861343-73-9//
5-Methyl-2-(1-methylethoxy)-4-(4-piperidinyl)benzenamine hydrochloride (1:2)1380575-45-0//
1-Chloro-5-isopropoxy-2-methyl-4-nitrobenzene1032903-50-6//
2-Isopropoxy-5-methyl-4-(piperidin-4-yl)aniline dihydrochloride hydrate1802250-63-0//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Ceritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →